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ARTICLE
Bioluminescence imaging of G protein-coupled
receptor activation in living mice
Mari Kono1, Elizabeth G. Conlon1, Samantha Y. Lux1, Keisuke Yanagida2, Timothy Hla 2 & Richard L. Proia 1
G protein-coupled receptors (GPCRs), a superfamily of cell-surface receptors involved in
virtually all physiological processes, are the major target class for approved drugs. Imaging
GPCR activation in real time in living animals would provide a powerful way to study their role
in biology and disease. Here, we describe a mouse model that enables the bioluminescent
detection of GPCR activation in real time by utilizing the clinically important GPCR,
sphingosine-1-phosphate receptor 1 (S1P1). A synthetic S1P1 signaling pathway, designed to
report the interaction between S1P1 and β-arrestin2 via the ﬁreﬂy split luciferase fragment
complementation system, is genetically encoded in these mice. Upon receptor activation and
subsequent β-arrestin2 recruitment, an active luciferase enzyme complex is produced, which
can be detected by in vivo bioluminescence imaging. This imaging strategy reveals the
dynamics and spatial speciﬁcity of S1P1 activation in normal and pathophysiologic contexts
in vivo and can be applied to other GPCRs.
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G protein-coupled receptors (GPCRs) (also known asseven-transmembrane-domain receptors) are the largestand most diverse gene superfamily in the human genome,
comprising greater than 3% of the protein coding genes1–3.
GPCRs are widely expressed, initiate cellular signal transduction
by a diverse array of extracellular ligands, and are involved in
virtually all physiological functions1,4. They are also extremely
important in clinical medicine as a major drug target class. It is
estimated that ~30% of approved pharmaceutical drugs are
directed to GPCRs4,5. Despite their enormous biological and
clinical importance, technologies to image GPCR activation in
their native physiologic environment in real time are lacking,
hampering a full understanding of the spatiotemporal
dynamics of their activation in vivo by endogenous or exogenous
ligands.
Sphingosine-1-phosphate receptor 1 (S1P1) is one of a ﬁve-
member GPCR family with high afﬁnity for the bioactive
sphingolipid, sphingosine-1-phosphate (S1P). It is ubiquitously
expressed among tissues and is highly enriched in endothelial
cells, where it serves as a key regulator of vascular barrier
function6–8. S1P1 also performs important actions in the immune
and nervous systems7. Its endogenous sphingolipid ligand, S1P, is
produced by all cells and is carried by lipoproteins and albumin
in the circulation7. S1P–S1P1 signaling has been linked to diverse
disease processes, including infection, multiple sclerosis, athero-
sclerosis, inﬂammatory bowel disease, and cancer6,7,9. FTY720
(ﬁngolimod/GilenyaTM), an S1P1 ligand, is an FDA-approved
drug for the treatment of remitting-relapsing multiple sclerosis10.
Ligand-activated GPCRs stimulate intracellular signaling
pathways via G proteins11,12 and other effectors, including β-
arrestins13–16. β-Arrestin binding to activated GPCRs also med-
iates receptor desensitization, internalization, and recycling. The
near-universal interaction between GPCRs and β-arrestins fol-
lowing agonist binding has been employed in assays for quanti-
fying receptor activation17–21. We recently developed a mouse
model for the detection of activated S1P1 in which a green
ﬂuorescent protein (GFP) reporter gene was activated22. This
model enabled the identiﬁcation of cells in which receptor acti-
vation has occurred in a cumulative manner, but it is not suited
for intravital imaging of real-time activation of GPCR signaling.
Here, we describe a genetic model in mice that enables the
imaging of S1P1 signaling in real time in the native physiological
environment of the receptor. These S1P1 signaling mice were
genetically designed to report the interaction between S1P1 and β-
arrestin2 upon receptor activation via ﬁreﬂy split luciferase
fragment complementation, which produces an active enzyme
complex whose activity can be detected by bioluminescence
imaging. The S1P1 signaling mice respond to synthetic ligands in
accordance to the speciﬁcity of the native receptor and the sta-
bility of pharmacologic agonists. The S1P1 signaling mice also
reveal the timing and anatomical localization of receptor activa-
tion by the endogenously synthesized S1P ligand during
endotoxin-induced systemic inﬂammation. This paradigm can be
applied to other members of the clinically important GPCR
family to enable the study of receptor activation in their in vivo
settings.
Results
Generation of S1P1 luciferase signaling mice. Our strategy for
imaging the activation of a GPCR in real time in living mice was
to adapt a ﬁreﬂy split luciferase complementation system21,23,24
for the detection of the interaction between ligand-activated S1P1
and β-arrestin2 (Fig. 1a). Both S1P1 and β-arrestin2 were
genetically modiﬁed as individual fusion proteins to carry inac-
tive, but complementary, fragments of luciferase. The S1P1 C
terminus was linked to the C-terminal fragment of ﬁreﬂy luci-
ferase (CLuc: amino acids #394–550), and the β-arrestin2 N
terminus was linked to the N-terminal fragment of ﬁreﬂy luci-
ferase (NLuc: amino acids #1–416). In this scheme, S1P1 activa-
tion will promote its interaction with β-arrestin2, facilitating the
association of the inactive luciferase fragments and producing an
active enzyme complex that, in the presence of substrates ATP
and D-luciferin, generates light that can be detected by biolu-
minescence imaging (BLI).
The efﬁcacy and speciﬁcity of the split luciferase complemen-
tation system for detection of S1P1 activation was tested by co-
transfection of expression vectors containing the S1P1–CLuc and
NLuc–β-arrestin2 fusion genes into U2OS cells. As a negative
interaction control, NLuc was fused to herpes simplex virus
thymidine kinase (HSV-tk) in place of β-arrestin2, and co-
transfected with S1P1–CLuc. In transfected cells treated with
vehicle, minimal luciferase activity was detected (Supplementary
Fig. 1a, b). However, addition of S1P or RP-001, a synthetic S1P1-
selective agonist25, caused a signiﬁcant increase in luciferase
activity in the S1P1–CLuc/NLuc–β-arrestin2-transfected cells
compared with the S1P1–CLuc/NLuc–HSV-tk-transfected cells.
These results demonstrate that the split luciferase complementa-
tion system, utilizing S1P1 and β-arrestin fusions, can speciﬁcally
detect S1P1 activation.
Gene targeting in embryonic stem cells was employed to
produce two individual mouse lines, each carrying one of the
fusion constructs (Supplementary Fig. 2a, b). One mouse line was
generated with the S1P1–CLuc fusion knocked in to the S1P1
coding region. In this conﬁguration, the native S1P1 promoter
elements were maintained to allow for expression of the S1P1
fusion gene in the endogenous context. The other mouse line was
established with the NLuc–β-arrestin2 fusion knocked in to the
safe harbor Rosa26 locus under control of the Rosa26 promoter
elements to provide a ubiquitous expression pattern, ensuring
that NLuc–β-arrestin2 would be co-expressed along with
S1P1–CLuc. The S1P1–CLuc knock-in mice were crossed
with the NLuc–β-arrestin2 knock-in mice to derive mice carrying
both alleles (Fig. 1a), which are termed S1P1 luciferase signaling
mice.
To determine whether the synthetic S1P1 signaling pathway
genetically encoded within the S1P1 luciferase signaling mice was
responsive to ligands with speciﬁcity similar to native S1P1,
primary mouse embryonic ﬁbroblasts (MEFs) derived from S1P1
luciferase signaling mice were utilized. Addition of S1P but not
vehicle rapidly induced bioluminescence in the MEFs (Fig. 1b).
Bioluminescence activity peaked within 3 min after addition of
S1P to the MEFs and was rapidly lost thereafter (Fig. 1b). This
loss of activity indicates that luciferase fragment complementa-
tion is transient and may reﬂect the rapid kinetics of S1P1
desensitization after activation and the subsequent dissociation of
the receptor–β-arrestin2 complex26. S1P and RP-001, a potent
synthetic S1P1-selective agonist25, induced luciferase activity in
the S1P1 luciferase signaling MEFs, but not in MEFs carrying only
the S1P1–CLuc or the NLuc–β-arrestin2 alleles (Fig. 1b, c),
showing that both components of the genetically encoded split
luciferase complementation system were necessary to report the
ligand-activated S1P1–CLuc interaction with NLuc–β-arrestin2.
Two structural analogs of S1P, lysophosphatidic acid (LPA) and
sphingosine, that are not ligands for S1P1 did not induce
bioluminescence when added to S1P1 luciferase signaling MEFs at
a concentration of 10−6 M (Fig. 1d, e).
The EC50 values for the activation of bioluminescence by S1P
and RP-001 in S1P1 luciferase signaling MEFs were determined to
be 19.4± 0.8 and 0.46± 0.02 nM, respectively (Fig. 1f). The
natural ligand dihydro-S1P (dhS1P)27, exhibited an EC50 for the
activation of bioluminescence of 32.4± 0.5 nM.
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Fig. 1 Generation of S1P1 luciferase signaling mice and detection of S1P1 activation. a (top), Schematic of the ﬁreﬂy split luciferase complementation design
to monitor S1P1–β-arrestin2 interactions. a (bottom), Mouse mating scheme to derive the S1P1 luciferase signaling (S1P1LS) mice. b–f Activation of S1P1 in
MEFs. b S1P1 luciferase signaling (S1P1LS) MEFs heterozygous for the S1P1–CLuc allele and homozygous for the NLuc–β-arrestin2 allele, MEFs heterozygous
for the S1P1–CLuc allele, and MEFs homozygous for the NLuc–β-arrestin2 allele were treated with S1P, RP-001 (10−6M), or vehicle in triplicate, and
immediately subjected to BLI. Intensities are shown in units of photons/sec/cm2/steradian; p/sec/cm2/sr. c The bioluminescence from three sequential 3-
min acquisitions in b was averaged. Data represent the mean± SEM. n= 3 for each group. d MEFs from S1P1 luciferase signaling (S1P1LS) mice were
exposed to S1P, sphingosine (Sph), or LPA (10−6M) in triplicate, and immediately subjected to BLI. Imaging was for sequential 3-min periods. e The
bioluminescence from three sequential 3-min acquisitions in d was averaged. Data represent the mean± SEM, n= 3 for each group. Experiments in b and d
were repeated twice. f Dose–response of S1P1 activation in S1P1 luciferase signaling MEFs. MEFs derived from S1P1 luciferase signaling mice, then exposed in
triplicate to various concentrations of S1P, RP-001, or dhS1P and immediately subjected to BLI for 30min. The experiment was repeated twice. Data
represent the mean± SEM. g, h Basal S1P1 activation in live mice. Three mouse genotypes were analyzed by BLI: heterozygous for the S1P1–CLuc allele
(S1P1–CLuc); homozygous for the NLuc–β-arrestin2 allele (NLuc–β-arrestin2); and heterozygous for the S1P1–CLuc allele and homozygous for the NLuc–β-
arrestin2 allele (S1P1LS). g A representative image comparing the basal bioluminescence activity in the three mouse lines. Mice were imaged in the supine
position. Red open rectangles representing regions of interest (ROI) were positioned around cephalic, thoracic, and epigastric regions. h The
bioluminescence activity was quantiﬁed by determining the total ﬂux (photons/sec; p/sec) in each ROI. Data represent the mean± SEM. n= 5 for
S1P1–CLuc, n= 8 for S1P1LS, n= 5 for NLuc–β-arrestin2. i Basal S1P1 activation in internal organs. S1P1 luciferase signaling (S1P1LS) mice (n= 3). A
representative image is shown (supine view). Arrow lymph node, Li liver, Sp spleen, Lu lung. P values were determined by one-way ANOVA followed by
Tukey’s multiple comparisons test; **P≤ 0.01, ***P≤ 0.001
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To determine if the genetically encoded split luciferase
complementation system could detect basal S1P1 activation
in vivo, S1P1 luciferase signaling mice, as well as mice carrying
only the S1P1–CLuc or NLuc–β-arrestin2 alleles, were subjected
to BLI while under anesthesia. Signiﬁcantly higher levels of
bioluminescence activity were detected in the S1P1 luciferase
signaling mice compared with the mice carrying only the
S1P1–CLuc or NLuc–β-arrestin2 alleles (Fig. 1g). We quantiﬁed
bioluminescence activity in the cephalic, thoracic, and epigastric
regions, as the activity varied between different body regions. The
highest activity was observed in the epigastric region, followed by
the thoracic and cephalic regions (Fig. 1h). To identify the
anatomical sites of basal S1P1 activation in S1P1 luciferase
signaling mice, S1P1 luciferase signaling mice were subjected to
BLI after surgically exposing the thoracic region and abdominal
cavity. The highest bioluminescence signals were detected in
lungs, in lymph nodes, and in the splenic region. Notably, no
signal was detected in the liver (Fig. 1i).
Treatment of S1P1 signaling mice with antagonist. To deter-
mine if the bioluminescence activity detected in S1P1 luciferase
signaling mice was the result of endogenous S1P1 activation, the
mice were injected with W14628, a potent S1P1-selective
antagonist (Fig. 2a). W146 treatment administered 30 min prior
to BLI signiﬁcantly lowered the bioluminescence in the S1P1
luciferase signaling mice by 70–80% in a dose-dependent manner
in the cephalic, epigastric, and thoracic regions compared with
the same mice treated with vehicle (Fig. 2b–d). The basal biolu-
minescence activity was completely restored in these S1P1
luciferase signaling mice 1 day post-W146 injection (Fig. 2b–d),
which is consistent with the rapid clearance reported for this
compound29. The inhibition of bioluminescence activity by
an S1P1 antagonist indicates that the basal activity detected in
the live mice is primarily the result of endogenous S1P1
activation.
Treatment of S1P1 signaling mice with agonists. FTY720 (ﬁn-
golimod/GilenyaTM), a sphingosine analog, is phosphorylated by
sphingosine kinases in vivo, and converted to a form that, at
nanomolar concentrations, activates S1P1, as well as S1P3, S1P4,
and S1P510. Its half-life in blood after oral administration in rats
is ~24 h30. To determine the time course of S1P1 activation by
FTY720 in the S1P1 luciferase signaling mice, the mice were
imaged prior to the administration of compounds and then
imaged serially at 1.5, 6, 24, and 48 h after intraperitoneal injec-
tion of each compound (Fig. 3). FTY720 concurrently induced
peak levels of bioluminescence activity in the cephalic, thoracic,
and epigastric regions at 6 h after injection. Signiﬁcant biolumi-
nescence activity continued to be detected at 24 and 48 h after
injection of FTY720, commensurate with the relatively long half-
life of the drug. BLI performed on FTY720-treated S1P1 luciferase
signaling mice (5 h after FTY720 treatment) with their internal
organs surgically exposed showed highly elevated biolumines-
cence signals over lung, lymph nodes, spleen, and liver (Supple-
mentary Fig. 3a). Compared with FTY720, RP-001 is a very short-
acting S1P1 agonist that decreases to undetectable levels in blood
by 8 h after administration in mice25 but is substantially more
potent, being effective at picomolar concentrations. RP-001
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Fig. 2 S1P1 activation after treatment with an S1P1 antagonist in live mice. a S1P1 luciferase signaling (S1P1LS) mice were serially injected with vehicle,
followed by the S1P1 antagonist W146 (5 or 10mg/kg, ip injection). b Representative repeat bioluminescence images of the same mice (top, supine view of
mouse # 1, 2, 3; bottom, prone view of mouse # 4, 5, 6) comparing the effects of vehicle with those of W146 (10mg/kg), 0.5 h after injection. BLI was also
performed 1 day after the W146 injection (post W146). Red open rectangles representing ROI were positioned around cephalic, thoracic, and epigastric
regions. c, d The bioluminescence activity was quantiﬁed by determining the total ﬂux (photons/sec; p/sec) in each ROI. Data acquired from supine (c)
and prone (d) views are shown. Data represent the mean± SEM. n= 6 for each group. P values were determined by one-way ANOVA followed by
Bonferroni’s multiple comparisons test; **P≤ 0.01, ***P≤ 0.001
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induced a peak of bioluminescence activity 1.5 h after adminis-
tration to S1P1 luciferase signaling mice in the cephalic, thoracic,
and epigastric regions. The bioluminescence signal was most
intense in the epigastric region. By 24 and 48 h after dosing, the
bioluminescence activity in RP-001-treated S1P1 luciferase sig-
naling mice declined to baseline levels (Fig. 3b–e).
LPS-induced systemic inﬂammation in S1P1 signaling mice.
S1P1 signaling is activated during systemic inﬂammation induced
by bacterial lipopolysaccharide (LPS); however, the timing and
anatomical distribution of receptor activation is not well estab-
lished22. In order to deﬁne these parameters, S1P1 luciferase
signaling mice were intraperitoneally injected with a sublethal
dose of LPS and then subjected to serial BLI at 2, 6, 24, 48, 72, and
96 h (Fig. 4). At 2 h after injection, a weak increase in biolumi-
nescence was observed primarily in the epigastric region, which
returned to baseline levels at 6 h. At 24 h after administration, the
bioluminescent signal was signiﬁcantly increased in the cephalic
and thoracic regions (Fig. 4b, c and Supplementary Fig. 5). At
48 h after administration, bioluminescent signal was elevated in
the thoracic region. At 72 h after administration, the strongest
signal was observed in the epigastric region. At 24 h after LPS
administration, BLI performed in S1P1 luciferase signaling
mice with surgically exposed internal organs demonstrated
bioluminescent signals induced over lungs, lymph nodes, spleen,
and liver (Supplementary Fig. 3b). These results show that LPS
induces heightened S1P1 activation in a sustained manner sys-
temically. In addition, the timing of S1P1 activation was dis-
tinctive for speciﬁc anatomical locations.
LPS-induced S1P1 activation by hematopoietically derived S1P.
A major fraction of circulating S1P is produced by hematopoie-
tically derived cells31. To determine if hematopoietic cell-derived
S1P is critical for systemic S1P1 activation during LPS-induced
inﬂammation, irradiated S1P1 luciferase signaling mice were
transplanted with sphingosine kinase-deﬁcient bone marrow
from plasmaS1Pless mice, which lack the ability to produce S1P
in the hematopoietic system31, and then subjected to BLI
(Fig. 5a). Plasma S1P and dhS1P levels were signiﬁcantly
decreased in the plasmaS1Pless bone marrow-transplanted mice
to ~20 and 10%, respectively, of the levels observed in control
bone marrow-transplanted mice (Fig. 5b). The residual S1P and
dhS1P in the plasmaS1Pless bone marrow-transplanted mice are
likely produced by the sphingosine kinase-replete endothelial cells
of the recipient mice32. After LPS treatment, mice transplanted
with control bone marrow exhibited signiﬁcantly increased bio-
luminescence activity compared with the plasmaS1Pless bone
marrow-transplanted mice in the thoracic region at 2, 6, and 24 h
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Fig. 3 S1P1 activation after treatment with S1P1 agonists in live mice. a S1P1 luciferase signaling (S1P1LS) mice were intraperitoneally injected with vehicle or
the S1P1 agonists FTY720 or RP-001, then subjected to BLI. bMice were subjected to imaging prior to injection (baseline, B/L) and 1.5, 6, 24, and 48 h after
injection. Representative bioluminescence images of the same three mice comparing the effects of vehicle (Veh), FTY720 (FTY), or RP-001 (RP) at the
speciﬁed time points. Mice were imaged in the supine position. Red open rectangles representing ROI were positioned around cephalic, thoracic, and
epigastric regions. c–e The bioluminescence was quantiﬁed by determining the total ﬂux (photons/sec; p/sec) in the cephalic (c), thoracic (d), and
epigastric (e) ROI. Data represent the mean± SEM. n= 5 for vehicle, n= 8 for FTY720, n= 6 for RP-001. P values between vehicle and agonist-injected
groups were determined by one-way ANOVA followed by Bonferroni’s multiple comparisons test; *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001
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and in the epigastric region at 24 h (Fig. 5c–f). The residual
bioluminescence activity in plasmaS1Pless bone marrow-
transplanted mice at 24 h after LPS treatment was signiﬁcantly
inhibited by the S1P1 antagonist W146 (Supplementary Fig. 4).
These results suggest that the low levels of dhS1P and S1P
remaining in these mice may provide some signaling activity. A
high degree of mortality occurred 24 h after LPS treatment in
S1P1 luciferase signaling mice transplanted with plasmaS1Pless
bone marrow, precluding further measurements. These results
indicate that hematopoietically derived S1P is responsible for a
signiﬁcant portion of the S1P1 activation that occurs in vivo
during LPS-induced inﬂammation.
S1P1 activation in the brain by inﬂammation. During LPS-
induced inﬂammation, bioluminescence activity was signiﬁcantly
increased in the cephalic region at 24 h (Fig. 4b, c and Supple-
mentary Fig. 5), raising the possibility that S1P1 may be activated
in the central nervous system (CNS). To determine if S1P1 sig-
naling was activated within the CNS and, if so, in which cell types,
we utilized the previously described S1P1 GFP signaling mice22.
In these mice, S1P1 activation is also based on interaction of the
GPCR with β-arrestin2; however, in this reporter system the
interaction leads to the proteolytic release of a transcription factor
tethered to S1P1 that enters the nucleus and activates a histone-
GFP reporter gene. The cells in which S1P1 activation occurs are
then stably marked with GFP-labeled nuclei (Fig. 6a). LPS was
administered to S1P1 GFP signaling mice and, 7 days later, brain
tissue was collected and sectioned, then the cortex, cerebellum,
and brainstem were examined for GFP-labeled cells (Fig. 6b, c).
Compared with vehicle-treated mice, LPS-treated mice exhibited
increased numbers of GFP-positive cells in each of these regions,
indicating that S1P1 activation had taken place in the CNS. The
GFP-positive cells appeared to be associated with the vasculature
and were CD31 positive, establishing their identity as endothelial
cells (Fig. 6c). Next, brain endothelial cells were isolated from
S1P1 luciferase signaling mice, treated with S1P or RP-001, and
examined by BLI. Bioluminescent activity was induced in the
brain endothelial cells in a dose-dependent manner, with RP-001
exhibiting a higher potency than S1P (Fig. 6d–f). Collectively, the
results indicate that S1P1 is activated in endothelial cells of the
neurovascular unit of the brain during systemic inﬂammation
induced by LPS and illustrate that the two different S1P1 signaling
mouse models provide complementary information for deﬁning
S1P1 activation in vivo.
Discussion
The luciferase signaling model for GPCR activation described
here affords a way to study GPCRs that was not previously
possible, yielding spatial and temporal information on the status
of endogenous receptor activation in real time in a living animal.
The nearly universal interaction between GPCRs with β-
arrestin13 was exploited to induce assembly of inactive fragments
of luciferase, producing an active enzyme complex and enabling
BLI upon activation of a GPCR, S1P1, in living mice. The in vivo
S1P1 signaling detection system was shown to be activated by
both synthetic and natural ligands of S1P1. BLI of the luciferase
signaling mice revealed the anatomical locations of homeostatic
S1P1 signaling, as well as the dynamics of S1P1 signaling under
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LPS to induce systemic inﬂammation, then subjected to BLI. b Representative bioluminescence images of the same three mice prior to LPS injection
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sec) in each ROI. Data represent the mean± SEM. n= 5. P values were determined between baseline and each time point by one-way ANOVA followed by
Bonferroni’s multiple comparisons test; **P≤ 0.01, ***P≤ 0.001
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inﬂammatory conditions. Although the resolution of the lucifer-
ase signaling model was limited to the identiﬁcation of signaling
at an organ or tissue level, the associated use of the previously
described GFP signaling model for S1P1 activation22, which relies
on transcription factor reporter gene activation, provided a means
to ultimately deﬁne S1P1 signaling sites at a cellular level. While
visualizing the source of the bioluminescent signal with single cell
resolution is not possible at present, detection of signaling in real-
time in vivo at a single cell level would be an important goal to
achieve.
We have demonstrated that the S1P1 luciferase signaling mice
can be used for the characterization of the in vivo signaling
activity of the receptor-active pharmacological compounds
FTY720 and RP-001 (Fig. 3). FTY72010, an approved drug (ﬁn-
golimod/GilenyaTM) used for the treatment of multiple sclerosis,
targets S1P receptors 1, 3, 4, and 5. It has a relatively long half-life
in blood30 and has been demonstrated to have diverse physiologic
effects in the immune, cardiovascular, and nervous systems7. RP-
001 is an S1P1-selective agonist that is more potent than FTY720,
but with a much shorter half-life in blood. Similar to FTY720, RP-
001 has been shown to trigger lymphopenia25. Administration of
these compounds to the S1P1 luciferase signaling mice enabled
determination of the timing of signaling and anatomical location
of signaling events, which indicates that this model will be gen-
erally useful for characterization of S1P1 modulators. The sig-
naling induced by RP-001 was relatively intense but decayed
rapidly, commensurate with its high potency and short half-life
(Fig. 3b–e). The very intense epigastic signal induced by RP-001
may reﬂect its rapid clearance in the liver. In contrast, the sig-
naling induced by FTY720 in vivo persisted over a long duration,
lasting up to 48 h (Fig. 3b–e). While consistent with the relatively
long half-life of the compound, prolonged signaling, and the
apparent absence of rapid desensitization would be compatible
with the existence of a receptor reserve. Under normal conditions,
a receptor reserve may underpin the long-term tonic S1P1 sig-
naling in the vascular endothelium. Compartmentalization of
S1P1 receptors may be a mechanism underlying such a receptor
reserve33,34. However, a different mechanism must operate on
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other cell types, such as lymphocytes, that rapidly downmodulate
S1P1 upon exposure to agonist25.
The S1P1 luciferase signaling mice provide the unique cap-
ability to detect the signaling activity of the endogenously pro-
duced natural ligand under basal and pathophysiological
conditions in real time. Under basal conditions, lung and lym-
phoid tissues showed the highest levels of signaling (Fig. 1i). This
is compatible with ample evidence for a functional S1P1 signaling
requirement in these tissues. In lung, blocking S1P1 signaling—
either by removal of S1P from the blood35 or by S1P1 antagon-
ism28,29—induced vascular leakage, indicating that S1P1 signaling
is critical to maintain vascular integrity in lung. In lymphoid
tissues, S1P1 signaling has been shown to be necessary for lym-
phocyte egress36 and for the positioning of cells, such as splenic
marginal zone B cells37. S1P1 signaling is also required in endo-
thelial cells in lymph nodes, notably on high endothelial venules,
which serve as the portals for lymphocyte entry to maintain their
vascular integrity38.
Under conditions of systemic inﬂammation induced by LPS
exposure, the S1P1 luciferase signaling mice reported region-
speciﬁc dynamics in S1P1 activation (Fig. 4). Liver showed little or
no signaling activity under basal conditions (Fig. 1i), but
exhibited dramatically increased S1P1 signaling during systemic
inﬂammation (Supplementary Fig. 3b). Hepatocytes have been
shown to express abundant S1P1 that is accessible for signaling in
response to FTY720 administration22. Based on the ﬁndings
reported here, they are apparently not exposed to sufﬁcient S1P
under basal conditions to stimulate signaling. However, during
conditions that induce vascular leakage, such as inﬂammation,
S1P derived from blood sources can stimulate S1P1 signaling in
hepatocytes and endothelial cells of liver, and endothelial cells in
lung, as has been demonstrated in an S1P1 GFP signaling mouse
model22. We have extended these ﬁnding here by showing
increased S1P1 signaling in brain endothelial cells during systemic
inﬂammation (Fig. 6).
The strategy used to produce the S1P1 luciferase signaling mice
provides a template for the development of a library of other
GPCR-signaling models. Creation of models for other GPCRs
that similarly interact with β-arrestin2 should only require the
derivation of a mouse with a receptor knock-in of the C-terminal
Luc fragment (amino acids #394–550). Subsequent cross-breeding
with the NLuc–β-arrestin2 mouse described here, which carries
the complementary luciferase N-terminal fragment (amino acids
#1–416), would yield unique GPCR-signaling models. These
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models can be used to gain new understandings of GPCR sig-
naling in normal and disease-speciﬁc biological contexts, and
enable in vivo analysis of GPCR-signaling perturbation by
receptor-active compounds, thereby facilitating drug develop-
ment for this important target class.
Methods
Reagents. S1P (d18:1), sphingosine (d18:1), and LPA (18:1) were purchased from
Avanti Polar Lipids; dhS1P (d18:0), LPS (Escherichia coli 055:B5; L2880), and
polyinosinic–polycytidylic ribonucleic acid (pIpC) (P0913) from Sigma-Aldrich;
FTY720 and W146 from Cayman; and RP-001 from Tocris.
Generation of S1P1 luciferase signaling mice. A split ﬁreﬂy luciferase enzyme
complementation system23,24 (Fig. 1a) was designed for detection of the S1P1 and
β-arrestin2 interaction after receptor activation. The fragments were fused to the
mouse S1pr1 (Accession: NM_007901.5) or Arrb2 (Accession: NM_145429.5)
coding regions via a linker (GGGGSGGGGS); the S1pr1 coding region was linked
to the C-terminal luciferase fragment (amino acids #394–550) to produce the
S1P1–CLuc fusion and the Arrb2 coding region was linked to the N-terminal
luciferase fragment (amino acids #1–416) to produce the NLuc–β-arrestin2 fusion.
Targeting vectors for mouse embryonic stem cells were constructed to insert the
S1P1–CLuc or NLuc–β-arrestin2 fusions into the S1pr1 or Rosa26 locus, respec-
tively (Supplementary Fig. 2a, b). In the S1pr1-targeting vector, the neomycin
resistance gene (NeoR), ﬂanked by loxP sites, was inserted downstream of the
fusion gene. In the Rosa26-targeting vector39, NeoR and a stop cassette (NeoR
Stop), ﬂanked by loxP sites, was placed upstream of the fusion gene. Gene targeting
in embryonic stem cells and generation of chimeric and heterozygous mice were
conducted as described previously22. The genotypes were determined by PCR
analysis of genomic DNA isolated from mouse tails. For genotyping of the
S1P1–CLuc fusion knock-in mice carrying NeoR, three primers were used: 5′-
AGAGGAATGTGGGCTGTTGATCCT-3′ (Primer 1); 5′-GGTGAA-
CATCCACCCACTATTCCA-3′ (Primer 2); and 5′-CCAAATTAAGGGC-
CAGCTCATTCC-3′ (Primer 3). Primers 1 and 2 detected the wild-type (WT)
allele and ampliﬁed a 290-bp fragment. Primers 2 and 3 detected the knock-in
allele carrying NeoR and ampliﬁed a 400-bp fragment. Forty cycles of 94 °C
(1 min), 60 °C (1 min), and 72 °C (1.5 min) were used for PCR. For genotyping of
the NLuc–β-arrestin2 knock-in mice bearing NeoR stop, three primers were used:
5′-GCACTTGCTCTCCCAAAGTC-3′ (Primer 4); 5′-GGCGGATCACAAGCAA-
TAAT-3′ (Primer 5); and 5′-TACCGGTGGATGTGGAATGT-3′ (Primer 6). Pri-
mers 4 and 5 detected the WT allele and ampliﬁed a 450-bp fragment. Primers 4
and 6 detected the knock-in allele bearing NeoR and the stop codon and ampliﬁed
a 580-bp fragment. Forty cycles of 94 °C (1 min), 63 °C (1 min), and 72 °C (1.5 min)
were used for PCR.
An EIIa Cre recombinase transgenic line40 (stock #003724, The Jackson
Laboratory) was crossed with the knock-in mice to remove the loxP-ﬂanked genes
in the germline. For genotyping of the S1P1–CLuc knock-in mice with NeoR
excised (–NeoR), three primers were used. Primers 1 and 7 (5′-
AGATGGCGGTAACTCTGAGG-3′) detected the WT allele and ampliﬁed a 400-
bp fragment. Primers 7 and 8 (5′-TAGTTGCCAGCCATCTGTTGTTTG-3′)
detected the S1P1–CLuc (–NeoR) knock-in allele and ampliﬁed a 510-bp fragment.
Forty cycles of 95 °C (1 min), 63 °C (1 min), and 72 °C (1.5 min) were used for
PCR. For genotyping of the NLuc–β-arrestin2 (–NeoR Stop) knock-in mice, three
primers were used. Primers 4 and 5 detected the WT allele as described above, and
primers 4 and 9 (5′-CCGTCTTCGAGTGGGTAGAA-3′) detected the NLuc–β-
arrestin2 (–NeoR Stop) knock-in allele and ampliﬁed a 560-bp fragment. Forty
cycles of 95 °C (1 min), 63 °C (1 min), and 72 °C (1.5 min) were used for PCR.
The scheme to derive S1P1 luciferase signaling mice is shown in Fig. 1a. Mice
heterozygous for S1P1–CLuc (–NeoR) knock-in mice were crossed with mice
heterozygous for NLuc–β-arrestin2 (–NeoR) knock-in mice to obtain double
heterozygotes, which were back crossed to mice heterozygous for NLuc–β-arrestin2
(–NeoR) to obtain mice heterozygous for S1P1–CLuc (–NeoR) and homozygous for
NLuc–β-arrestin2 (–NeoR). S1P1 luciferase signaling mice that were heterozygous
for the S1P1–CLuc (–NeoR) allele and homozygous for the NLuc–β-arrestin2
(–NeoR Stop) allele showed a higher bioluminescence signal after FTY720
treatment than mice heterozygous for both of these alleles (Supplementary Fig. 6).
For this reason, mice heterozygous for the S1P1–CLuc (–NeoR) allele and
homozygous for the NLuc–β-arrestin2 (–NeoR stop) allele were used in S1P1
luciferase signaling mouse studies. Animals were housed in a speciﬁc pathogen-free
facility and provided food and water ad libitum. Age-matched offspring of both
sexes (2–5 months old) were used for experiments. The mice were at the initiation
of experiments. The sample size was selected based on expected effect size. No
randomization method was employed. Investigators were blinded to the genotype
of animals during data analysis. No experimental animals were excluded from the
analysis.
BLI of S1P1 activation in cells and mice. S1P1–CLuc, NLuc–β-arrestin2, and
NLuc–HSV-tk (accession: Q9QNF7.1) fusions were prepared using a linker
(GGGGSGGGGS) sequence as described above and cloned into pcDNA3.1
(Thermo Fisher Scientiﬁc). U2OS cells (American Type Culture Collection) were
plated in 24-well plates (1.5 × 105 cells/well) and transfected by pcDNA3.1-
S1P1–CLuc (10 ng) together with pcDNA3.1-NLuc–β-arrestin2 (500 ng) or
pcDNA3.1-NLuc–HSV-tk (500 ng) using Lipofectamine 3000 (Thermo Fisher
Scientiﬁc). The media was replaced 24 h after transfection with DMEM containing
10% charcoal-stripped FBS and the cells incubated for 16 h. The media was then
changed to DMEM with 0.1% FBS for 4 h, and then treated simultaneously with
150 μg/ml D-luciferin (K + Salt Bioluminescent Substrate, PerkinElmer) and S1P,
RP-001, or vehicle. Bioluminescence activity was immediately detected with an
in vivo imaging system (IVIS Lumina II, PerkinElmer).
S1P1 luciferase signaling MEFs were isolated from E12.5 embryos with three
different genotypes: heterozygous for the S1P1–CLuc allele; homozygous for the
NLuc–β-arrestin2 allele; and heterozygous for the S1P1–CLuc allele and
homozygous for the NLuc–β-arrestin2 allele (S1P1 luciferase signaling mice). The
MEFs were plated in 24-well plates (2 × 105 cells/well) and incubated for 16 h in
DMEM containing 10% charcoal-stripped FBS for 16 h followed by DMEM with
0.1% FBS for 4 h. After treatment with agonists, bioluminescence activity was
measured immediately as described above.
S1P1 luciferase signaling mouse brain endothelial cells were prepared as
previously described41. The endothelial cells in 24-well plates (105/well) were
incubated in medium (DMEM high glucose [12–709 F, LONZA], 5 μg/ml
endothelial cell growth factor [BT-203, Biomed Tech], 100 μg/ml heparin, 100 U/
ml penicillin, and 100 U/ml streptomycin) containing 10% charcoal-stripped FBS
for 16 h followed by medium containing 0.1% BSA for 4 h. After treatment with
agonists, bioluminescence activity was immediately detected as described above.
For BLI in live mice, the hair was removed with a clipper and hair removal
cream. XenoLight Rediject D-luciferin (PerkinElmer) (150 mg/kg BW) was injected
intraperitoneally, and the mice were subjected to BLI using an in vivo imaging
system (IVIS Lumina II). During the imaging, the mice were anesthetized with
isoﬂurane (Baxter) using an XGI-8 gas anesthesia system (PerkinElmer). Eye
lubricant (Puralube Vet Ointment, Dechra) was applied during the anesthesia.
Imaging parameters were: binning =medium (8), ﬁeld of view = 12.5 × 12.5 cm, f/
stop = 1. Each image exposure lasted 5 min, and a total of four sequential images
were captured. The second 5-min image was used in all experiments. Images were
analyzed using Living Image Software (PerkinElmer). Regions of interest (ROI)
were drawn around each body region and the total ﬂux (photons/s) was
determined.
For BLI of internal organs, mice were anesthetized by intraperitoneal injection
of ketamine (180 mg/kg BW)—xylazine (12 mg/kg BW), and after 15 min received
an intraperitoneal XenoLight Rediject D-luciferin (PerkinElmer) injection
(500 mg/kg BW). The ventral skin was incised along the midline to expose the
internal organs. Bioluminescence activity was immediately detected with an in vivo
imaging system (IVIS Lumina II) with four acquisitions lasting 5 min each.
In some mouse studies, prior to imaging, mice were intraperitoneally injected
with FTY720 (1 mg/kg BW; vehicle, 43% ethanol-7% DMSO in PBS), RP-001
(1 mg/kg BW; vehicle, 43% ethanol-7% DMSO in PBS), W146 (5 and 10 mg/kg
BW; vehicle, 10 mM sodium carbonate-2% (2-hydroxypropyl)-β-cyclodextrin in
water), or LPS (16 mg/kg BW; vehicle, PBS).
Analysis of S1P1 activation in brain. S1P1 GFP signaling mice have been pre-
viously described22. LPS (16 mg/kg BW; vehicle, PBS) was injected intraper-
itoneally into S1P1 GFP signaling mice. Seven days after the injection, the mice
were perfused with normal saline followed by chilled 4% paraformaldehyde in
0.1 M phosphate buffer (pH 7.4) and the brains were harvested. The tissues were
post ﬁxed in 4% paraformaldehyde for 4 h and incubated in 30% sucrose in 0.1 M
phosphate buffer (pH 7.4) at 4 °C for 2 days, then embedded in OCT (Sakura) and
sectioned at 7-μm thickness. For immunostaining, nonconjugated primary anti-
body for mouse CD31 (clone SZ31, Dianova) and ﬂuorescently labeled secondary
antibody (donkey anti-rat IgG Cyanine Cy3, Jackson ImmunoResearch Labora-
tories) were used. The images were captured with an inverted laser scanning
confocal microscope (LSM 780, Carl Zeiss Microscopy) using Zeiss Zen
2012 software.
Preparation of plasma S1P-deﬁcient S1P1 luciferase signaling mice.
Sphk1ﬂox/ﬂox Sphk2−/− Mx1-cre mice were obtained by breeding Sphk1ﬂox/ﬂox mice
(stock #030038-UCD, MMRRC), Sphk2−/− mice42 and Mx1-cre mice43 (stock
#003556, The Jackson Laboratory). Plasma S1P-deﬁcient (plasmaS1Pless) mice
were prepared by injection of pIpC into Sphk1ﬂox/ﬂox Sphk2−/− Mx1-cre pups as
described31. Controls (Sphk1ﬂox/ﬂox Sphk2−/−) were similarly bred and injected with
pIpC. Bone marrow cells were isolated from the femurs and tibias of adult control
and plasmaS1Pless mice 4 weeks after pIpC injection. A single cell suspension of
control or plasmaS1Pless bone marrow cells (1 × 107 cells/mouse) in 0.2 ml saline
was injected into the tail vein of irradiated (9 Gy) S1P1 luciferase signaling mice.
These mice, termed control and plasmaS1Pless S1P1 luciferase signaling mice,
respectively, were used 20 weeks after transplantation.
Sphingolipid analysis. S1P and dhS1P were measured by HPLC-tandem MS by
the Lipidomics Core at the Medical University of South Carolina on a Thermo
Finnigan TSQ 7000 triple quadrupole mass spectrometer (Thermo Fisher
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Scientiﬁc), operating in a multiple reaction monitoring-positive ionization mode as
described44.
Statistical analysis. GraphPad Prism v.6.0 software was used for statistical ana-
lyses. To determine the signiﬁcance between three or more test groups, analysis of
variance (ANOVA) was used followed by either Bonferroni’s for comparison to the
control group or Tukey’s to compare all groups. Two-tailed Student’s t-test was
used for the direct comparison of two groups. In all cases, P≤ 0.05 was considered
statistically signiﬁcant.
Study approval. All animal procedures were approved by the Animal Care and
Use Committee of the National Institute of Diabetes and Digestive and Kidney
Diseases and performed in accordance with the National Institutes of Health
guidelines.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within this paper or its Supplementary Information ﬁle or are
available from the corresponding author on request.
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